
This study validates the AI-based tool, Stratipath Breast, for risk stratification of breast cancer patients using digital histopathology images. The tool effectively stratified patients into high- and low-risk groups, particularly within the ER+/HER2- and NHG2/ER+/HER2- subgroups, showing significant prognostic value. These findings support its potential use in guiding adjuvant chemotherapy decisions and improving treatment outcomes while reducing costs.
Like
Save
Share